For The Asking, A Check Is In The Mail To Help Pay For Costly Drugs
It’s a little-known secret that patients can get thousands of dollars directly from a drugmaker.
Showing 81 - 100 of 127
-
-
Government Investigation Finds Flaws In the FDA’s Orphan Drug Program
A probe by the Government Accountability Office cites breakdowns in the Food and Drug Administration program that approves drugs for rare diseases.
By Sarah Jane Tribble and Sydney Lupkin -
Trump Adds A Global Pricing Plan To Wide Attack On Drug Prices, But Doubts Persist
Over the past five months, the Trump administration has proposed a series of reforms to lower the cost of prescription drugs.
-
TV Ads Must Trumpet Drug Prices, Trump Administration Says. Pharma Tries A Plan B.
Drug pricing is a top issue in the run-up to the midterm elections.
By Shefali Luthra and Sarah Jane Tribble -
Drugmakers Play The Patent Game To Lock In Prices, Block Competitors
Pharmaceutical companies like Purdue Pharma, maker of OxyContin, often win patents for incremental changes with debatable value. Now there’s a twist involving an opioid treatment.
-
Unwitting Patients, Copycat Comments Play Hidden Role In Federal Rule-Making
As HHS decided to cut $1.6 billion in drug payments to hospitals, it weighed thousands of comments generated by a pharmaceutical-funded advocacy group.
-
Trump Administration Sinks Teeth Into Paring Down Drug Prices, On 5 Key Points
Instead of waiting for congressional action, federal regulators are looking at a series of actions to spur competition and drive down the cost of medicines.
-
Déjà Voodoo: Pharma’s Promises To Curb Drug Prices Have Been Heard Before
Several major drugmakers vow to contain drug prices, but similar pledges since the 1990s have not had much impact.
By Jay Hancock and Sarah Jane Tribble -
Top Policy Expert’s Ties To Giant Drugmaker Often Go Unstated
Dr. Mark McClellan joined Johnson & Johnson’s board of directors after leaving the FDA, but the connection often isn’t mentioned in research papers or public events.
-
Trump Vows (Again) To Lower Drug Prices But Skeptics Doubt Much Will Change
President Donald Trump’s much-awaited speech about slashing drug costs was long on rhetoric but short on specifics that will reduce prices.
By Sarah Jane Tribble and Liz Szabo -
For The Babies Of The Opioid Crisis, The Best Care May Be Mom’s Recovery
Research is just beginning on infants born with neonatal abstinence syndrome, and doctors are optimistic that normal development is possible. Monitoring the families and making sure parents are treated for addiction is key.
-
Dissecting The Rhetoric Vs. Reality Of Trump’s Tough Talk On Drug Prices
President Donald Trump’s upcoming speech on drug prices comes after months of public comments and debate about tackling the issue.
-
How A Drugmaker Turned The Abortion Pill Into A Rare-Disease Profit Machine
An abortion drug invented decades ago is being used to treat Cushing’s syndrome — and it’s bringing in tens of millions of dollars a year.
-
FDA Head Vows To Tackle High Drug Prices And Drugmakers ‘Gaming The System’
In an exclusive interview, FDA Commissioner Scott Gottlieb describes what he’s doing to spur competition and bring down drug prices.
By Sarah Jane Tribble and Liz Szabo -
Trump’s Budget Proposal Swings At Drug Prices With A Glancing Blow
The Trump administration rolled out a list of actions to attack drug prices, but most dance around the edges.
-
FDA Chief Says He’s Open To Rethinking Incentives On Orphan Drugs
The FDA’s Scott Gottlieb says the agency is focused on the big picture, and he wants to know why pharma churns out drugs for some rare diseases but not for others.
-
Experts Tell Congress How To Cut Drug Prices. We Give You Some Odds.
Some of the nation’s most influential scientists recommend eight steps to lower drug prices. KHN takes the political temperature and tells you the chances of Congress acting on them.
-
Patients With Rare Diseases And Congress Square Off Over Orphan Drug Tax Credits
The House and Senate want to reduce or eliminate federal tax credits for “orphan drugs” used to treat rare diseases, but patients are fighting against the plan.
-
Heated And Deep-Pocketed Battle Erupts Over 340B Drug Discount Program
Drugmakers, hospitals and lawmakers are taking sides in a showdown over a discount program that covers drug purchases at some hospitals.
-
Medicare Seeks Comment On Ways To Cut Costs Of Part D Drugs
Medicare is examining how rebates and discounts could be shared in some way with Part D beneficiaries to reduce their out-of-pocket costs.
Sign Up For Our Newsletter
Stay informed by signing up for the Morning Briefing and other emails: